全视网膜光凝术联合玻璃体腔注射雷珠单抗治疗增生性糖尿病视网膜病变的疗效比较OA

Objective To explore the clinical comparative study of panretinal photocoagulation(PRP)and intra-vitreal injection of Ranibizumab(RBZ)in the treatment of proliferative diabetic retinopathy(PDR).Methods A prospec-tive case-control study.A total of 106 patients with proliferative diabetic retinopathy(PDR)who visited between June 2022 and November 2023 were enrolled.Among them,there were 42 patients with type I diabetes and 84 patients with type II diabetes,with an average age of(52.49±3.56).According to the treatment plan,the patients were divided into PRP group and combined treatment group(PRP+RBZ).All patients signed an informed consent form before proceeding with the study.The weight,height,demographics,vital signs and medical history of the participants were recorded through the baseline visit.The incidence of adverse events during the study was recorded and compared.The patients'neovasculariza-tion of the optic disc(NVD),retinal neovascularization elsewhere(NVE)and total neovascularization through fluorescein angiography(NVT)reduction amount were compared.Optical coherence tomography(OCT)was used to measure central macular thickness(CMT).The patient's best corrected visual acuity(BCVA)was measured according to the early treat-ment diabetic retinopathy study(ETDRS)protocol.Results A total of 54 adverse events occurred in the study.There was no difference in the incidence of vitreous hemorrhage in the PRP treatment group 7(12.96%)and the combination treat-ment group 5(9.61%)(P>0.05).The combination treatment group was compared with the PRP treatment group,in-creased intraocular pressure,systemic adverse reactions and adverse incidence of vascular events decreased(all P<0.05),and the overall incidence of adverse events in the combined treatment group was lower than that in the PRP treatment group(P<0.05).Compared with the PRP treatment group,the proportion of NVD,NVE and NVT decreased in the combined treatment group was higher(all P<0.05).There was no difference in the average macular thickness of the Chinese and Brit-ish visual fields between the two groups before the treatment(P>0.05).At the third month,the macular thickness of the combined treatment group at the 8th and 12th months were lower than that of the PRP treatment group(P<0.05).There was no difference in the baseline BCVA before the treatment(P>0.05).At the third month after the treatment,there was no difference in BCVA between the two groups(P>0.05),and the combined treatment at the 8th and 12th month was lower than the PRP treatment group BCVA(P<0.05).Compared with the PRP treatment group,the significant rate and total ef-fective rate of combined treatment group increased(P<0.05),and the general rate and inefficiency of the combined treat-ment group were lower than that of the PRP treatment group(P<0.05).Conclusions PRP+ranibizumab intravitreal in-jection of ranibizumab combined therapy can increase the success rate of PRP to cure neovascularization,improve vision and reduce side effects.